MA51615A - Polytherapie pour le traitement ou la prévention du cancer - Google Patents

Polytherapie pour le traitement ou la prévention du cancer

Info

Publication number
MA51615A
MA51615A MA051615A MA51615A MA51615A MA 51615 A MA51615 A MA 51615A MA 051615 A MA051615 A MA 051615A MA 51615 A MA51615 A MA 51615A MA 51615 A MA51615 A MA 51615A
Authority
MA
Morocco
Prior art keywords
polytherapy
cancer
prevention
treatment
Prior art date
Application number
MA051615A
Other languages
English (en)
Inventor
Alexander Stevenson
Original Assignee
4D Pharma Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1800927.4A external-priority patent/GB201800927D0/en
Priority claimed from GBGB1801502.4A external-priority patent/GB201801502D0/en
Priority claimed from GBGB1805941.0A external-priority patent/GB201805941D0/en
Priority claimed from GBGB1806572.2A external-priority patent/GB201806572D0/en
Priority claimed from GBGB1808631.4A external-priority patent/GB201808631D0/en
Application filed by 4D Pharma Res Ltd filed Critical 4D Pharma Res Ltd
Publication of MA51615A publication Critical patent/MA51615A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
MA051615A 2018-01-19 2019-01-18 Polytherapie pour le traitement ou la prévention du cancer MA51615A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1800927.4A GB201800927D0 (en) 2018-01-19 2018-01-19 Combination therapy for treating or preventing cancer
GBGB1801502.4A GB201801502D0 (en) 2018-01-30 2018-01-30 Combination therapy for treating or preventing cancer
GBGB1805941.0A GB201805941D0 (en) 2018-04-10 2018-04-10 Combination therapy for treating or preventing cancer
GBGB1806572.2A GB201806572D0 (en) 2018-04-23 2018-04-23 Combination therapy for treating or preventing cancer
GBGB1808631.4A GB201808631D0 (en) 2018-05-25 2018-05-25 Combination therapy for treating or preventing cancer

Publications (1)

Publication Number Publication Date
MA51615A true MA51615A (fr) 2020-11-25

Family

ID=65278398

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051615A MA51615A (fr) 2018-01-19 2019-01-18 Polytherapie pour le traitement ou la prévention du cancer

Country Status (14)

Country Link
US (2) US20210060086A1 (fr)
EP (1) EP3740220A1 (fr)
JP (1) JP2021516662A (fr)
KR (1) KR20200110342A (fr)
CN (1) CN111727047A (fr)
AU (1) AU2019210004A1 (fr)
BR (1) BR112020014565A2 (fr)
CA (1) CA3088338A1 (fr)
IL (1) IL276074A (fr)
MA (1) MA51615A (fr)
MX (1) MX2020007664A (fr)
SG (1) SG11202006873UA (fr)
TW (1) TW201934139A (fr)
WO (1) WO2019141998A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023072968A1 (fr) * 2021-10-25 2023-05-04 4D Pharma Research Ltd Compositions comprenant des souches bactériennes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
WO2008050209A1 (fr) 2006-10-27 2008-05-02 Pfizer Products Inc. Capsules dures en hydroxypropylméthylcellulose et leur procédé de fabrication
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
CA2987129A1 (fr) * 2015-06-01 2016-12-08 The University Of Chicago Traitement du cancer par manipulation de la flore microbienne commensale
NZ742787A (en) * 2015-11-20 2020-02-28 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520497D0 (en) * 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
JP6978514B2 (ja) * 2017-05-24 2021-12-08 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited 細菌株を含む組成物

Also Published As

Publication number Publication date
CA3088338A1 (fr) 2019-07-25
SG11202006873UA (en) 2020-08-28
US20230277602A1 (en) 2023-09-07
MX2020007664A (es) 2020-09-14
BR112020014565A2 (pt) 2020-12-08
KR20200110342A (ko) 2020-09-23
EP3740220A1 (fr) 2020-11-25
CN111727047A (zh) 2020-09-29
AU2019210004A1 (en) 2020-08-13
IL276074A (en) 2020-08-31
US20210060086A1 (en) 2021-03-04
WO2019141998A1 (fr) 2019-07-25
JP2021516662A (ja) 2021-07-08
TW201934139A (zh) 2019-09-01

Similar Documents

Publication Publication Date Title
MA49144A (fr) Polythérapies pour le traitement du cancer
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
MA45037A (fr) Polythérapie à base d'arnm pour le traitement du cancer
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA45192A (fr) Traitement d'association
MA48637A (fr) Polythérapies pour le traitement du cancer
MA45146A (fr) Dérivés de pyrazolopyridine pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA43000A (fr) Polythérapie pour le traitement de tumeurs malignes
MA51139A (fr) Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer
MA47719A (fr) Esketamine pour le traitement de la dépression
MA51613A (fr) Polythérapie pour le traitement ou la prévention du cancer
MA47604A (fr) Anticorps anti-pd-1 pour le traitement du cancer du poumon
MA54925A (fr) Compositions pour le traitement de troubles acido-basiques
MA42999A (fr) Polythérapie pour le traitement de malignités
MA41555A (fr) Polythérapie pour le traitement du cancer
MA43170A (fr) Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer
MA50943A (fr) Anticorps anti-liv1 humanisés pour le traitement du cancer du sein
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA51738A (fr) Composés pour le traitement de la douleur
MA52499A (fr) Associations pour le traitement du cancer
MA52627A (fr) Traitement du cancer
MA45973A (fr) Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple